Minerva Neurosciences | NERV - Current Liabilities


Minerva Neurosciences reported $2.29M in Current Liabilities for its fiscal quarter ending in December of 2025.





Current Liabilities Change Date
Acadia Pharmaceuticals USD 305.52M 28.41M Mar/2026
Adma Biologics USD 73.54M 4M Mar/2026
ALKERMES USD 599.5M 56.06M Mar/2026
Alterity Therapeutics Limited AUD 1.73M 2.77M Dec/2025
AstraZeneca USD 32.57B 1.95B Mar/2026
BioCryst Pharmaceuticals USD 195.39M 675K Mar/2026
Bristol-Myers Squibb USD 19.16B 4.26B Mar/2026
Cipla INR 70.14B 7.16B Mar/2026
Clal Biotechnology ILS 6.66M 3.75M Dec/2023
Compugen USD 22.57M 2.29M Dec/2025
CSL USD 4.61B 207M Dec/2025
Eli Lilly USD 36.63B 1.41B Mar/2026
Esperion Therapeutics USD 300.36M 451K Mar/2026
GlaxoSmithKline GBP 22.43B 1.04B Mar/2026
Grifols EUR 2.37B 156.97M Dec/2025
Halozyme Therapeutics USD 363.21M 186.12M Mar/2026
Ionis Pharmaceuticals USD 717M 66M Mar/2026
J&J USD 57.72B 3.59B Mar/2026
Merck USD 26.94B 1.38B Mar/2026
Minerva Neurosciences USD 2.29M 381K Dec/2025
Neurocrine Biosciences USD 831.7M 88.3M Mar/2026
Novartis USD 31.37B 4.1B Mar/2026
Novavax USD 342.46M 117.49M Mar/2026
Pfizer USD 34.35B 2.64B Mar/2026
Roche Holding CHF 28B 421M Dec/2025
Sanofi EUR 30.01B 1.66B Mar/2026
Takeda JPY 2.43T 180.65B Mar/2026
Vanda Pharmaceuticals USD 145.16M 27.29M Dec/2025